Factor VII-Antithrombin Predicts Mortality in Coronary Artery Disease

This article originally appeared here.
Patients with FVIIa-AT levels above median at baseline have two-fold increased mortality
Patients with FVIIa-AT levels above median at baseline have two-fold increased mortality

(HealthDay News) — Activated factor VII-antithrombin complex (FVIIa-AT) levels correlate with increased mortality risk in patients with coronary artery disease (CAD), according to a study published online Jan. 27 in the Journal of Thrombosis and Haemostasis.

Nicola Martinelli, MD, PhD, from the University of Verona in Italy, and colleagues examined FVIIa-AT plasma concentrations in 686 subjects with (546 subjects) or without (140 subjects) angiographically-proven CAD. Patients with CAD were followed for total and cardiovascular mortality.

The researchers found that FVIIa-AT levels did not differ for CAD and CAD-free subjects (84.8 and 83.9 pM, respectively). During a 64-month median follow-up, the risk of both total and cardiovascular mortality was increased two-fold for patients with FVIIa-AT levels higher than the median at baseline (≥79 pM), within the CAD population. After adjustment for sex, age, and other predictors of mortality, the results were confirmed (hazard ratio for total mortality, 2.05; hazard ratio for cardiovascular mortality, 1.94; with slight improvement of C-statistic over traditional risk factors). Increased thrombin generation was also seen in association with high FVIIa-AT levels.

"This preliminary study suggests that plasma concentration of FVIIa-AT is a thrombophilic marker of total and cardiovascular mortality risk in patients with clinically stable CAD," the authors write.

Two authors disclosed financial ties to Diagnostica Stago.

Abstract
Full Text (subscription or payment may be required)

Loading links....